Up­dat­ed: Ed­i­tas ed­its pipeline, lays off 20% and says bye to CSO to kick off #JPM23 

One of the ear­ly gene edit­ing hope­fuls, Ed­i­tas Med­i­cine, has strug­gled to keep its ship on the right path. The biotech’s lat­est woes in­clude pipeline cuts, lay­offs and the CSO’s ex­it.

The Boston-area biotech is let­ting go 20% of its work­force, get­ting rid of sci­ence chief Mark Shear­man at the end of March and re­tun­ing the clin­i­cal fo­cus. The search for a new CSO is al­ready un­der­way, the biotech said Mon­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER